,
Mati Therapeutics

Coming – October 9

An Eye-Opening Opportunity In Ophthalmic Care

Date and Time

October 9

–

4:00 PM ET 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

Mati Therapeutics is poised to transform ophthalmic care with its Evolute Punctal Plug Drug Delivery System (PPDS), a disruptive platform that replaces traditional eye drops with a safe, effective, and compliance-free alternative. Eye drops are a $6B market but suffer from poor adherence, inefficiency, and patient dissatisfaction. Evolute solves these challenges by delivering sustained, controlled doses of medication directly to the ocular surface for up to six months—improving outcomes while reducing side effects and ensuring 100% compliance.

Two lead product, nepafenac (NSAID) for post-cataract pain and dexamethasone (steroid) for post-cataract inflammation, are ready for Phase III pivotal trials with high probabilities of success, supported by strong Phase II data. Beyond cataract care, Mati is advancing a glaucoma program, addressing the largest ophthalmic opportunity with potential U.S. sales of $600M, and preparing additional programs in dry eye and ocular allergy.

Mati anticipates rapid revenue growth post-launch, exceeding $500M annually from its cataract portfolio alone, with operating margins accelerated by its low-cost, in-house manufacturing facility. Multiple large pharmaceutical companies—including Alcon, J&J, and Novartis—have demonstrated elevated interest in ophthalmology acquisitions, positioning Mati as a prime candidate for M&A once products reach the market.

Join our online event with Bob Butchofsky, founder and CEO of Mati Therapeutics to hear why this is a compelling opportunity with multiple shots on goal, strong near-term catalysts, and attractive exit potential via acquisition or IPO.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.